Odyssey Therapeutics Reports OD-001 Clinical Trial Data

The Boston-based company released Phase 2a trial results for its oral treatment for moderate-to-severe ulcerative colitis.

Updated on Oct. 20, 2026 in Diseases — General

Odyssey Therapeutics Reports OD-001 Clinical Trial Data

Live Poll

Do you trust that pharmaceutical companies are effectively developing new treatments for autoimmune and inflammatory diseases?

Odyssey Therapeutics has announced positive Phase 2a clinical trial results for its oral drug candidate, OD-001, designed for patients with moderate-to-severe ulcerative colitis. The study met its primary endpoint by achieving a mean reduction in the modified Mayo score at Week 12.

Why it matters

The trial aimed to establish the safety, tolerability, and efficacy of the oral treatment in a patient population experiencing moderate-to-severe symptoms. Advancing this therapy could provide a new oral intervention option for those living with the chronic inflammatory bowel disease.

The study evaluated 56 efficacy-evaluable patients who showed a mean reduction of 2.4 points in their modified Mayo score. Participants receiving 20 mg twice daily achieved a 21% symptomatic remission rate at Week 2.

The players

Odyssey Therapeutics

This Boston-based biotechnology company focuses on developing precision medicines for inflammatory diseases and oncology.

The details

The trial utilized an open-label, dose-ranging design, with patients receiving 10 mg or 20 mg doses twice daily. Researchers also conducted exploratory analyses on paired colonic biopsies taken at the start and end of the 12-week induction period.

October 20, 2026: Results were presented at UEG Week in Barcelona.
Week 2: Patients on the 20 mg dose reached a 21% symptomatic remission rate.
Week 12: Trial induction period concluded for participating patients.
Second half of 2027: Topline results for future trials are expected.

Health Landscape

The company's plan to test OD-001 in combination with vedolizumab follows the industry pattern of exploring combination therapies to improve patient outcomes. This strategy aims to build upon established treatment protocols for chronic inflammatory bowel conditions.

The potential development of an oral therapeutic could change daily treatment routines for individuals with moderate-to-severe ulcerative colitis. Future trial outcomes will help clarify the safety profile and whether this drug could serve as an effective alternative to current therapies.

The takeaway

The successful completion of this trial marks a key step in evaluating oral medication as a viable path for managing ulcerative colitis. Patients and providers should monitor future Phase 2b trial results to see how this therapy compares against standard placebo-controlled benchmarks.

What happens next

Odyssey Therapeutics is scheduled to launch a randomized, placebo-controlled Phase 2b monotherapy trial and a randomized, active-controlled Phase 2a combination trial with expected topline results in the second half of 2027.